Fixed-dose combination for newly diagnosed hypertensive patients, first line: where are we?

The conference focused on the 2018 ESC/ISH hypertension guidelines recommendations to treat hypertensive patients with fixed-dose combinations, from diagnosis, and reduce low control rates (30%1).

The European Society of Cardiology of 2018/European Society of Hypertension (ESC / ESH) for the management of arterial hypertension2 recommend in most cases to start antihypertensive treatment with two drugs, preferably in a combination in a single tablet, of a angiotensin converting enzyme inhibitor (ACEI) in association with a calcium channel blocker (CCB).

He emphasized that it is better to treat a newly diagnosed hypertensive patient early with a low-dose two-drug combination such as Coveram 3.5/2.5, rather than monotherapy, thanks to its dual mechanism of action.

Coveram 3.5/2.5 is much more effective and faster in reducing BP(-30mmHg3), with 24-hour4 control and only cardio-metabolic protection (-19%)5, compared to ARA II monotherapies, demonstrated by scientific evidence.

www.thelancet.com Vol 398 September 11, 2021 2. Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension ESC/ESH task force for the management of arterial hypertension. J Hypertens.2018;36(12):2284–309 3. Fleig V et al. Adv Ther. 2018;35:353-366 2. 4. Triplixam SmPC 5. Poulter N et al. Am J Cardiovasc Drugs. 2019;19³:313-323. Coveram 3.5mg/2.5 mg is indicated for the treatment of essential hypertension in adults.